Holen Sie sich die Stockscreener-App
1.21
0.83%
0.01
Handel nachbörslich:
1.21
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.20
Offen:
$1.2
24-Stunden-Volumen:
139.84K
Relative Volume:
0.14
Marktkapitalisierung:
$20.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.14M
KGV:
-0.2027
EPS:
-5.97
Netto-Cashflow:
$-28.20M
1W Leistung:
-1.63%
1M Leistung:
-6.92%
6M Leistung:
-23.90%
1J Leistung:
-90.65%
1-Tages-Spanne:
$1.18
$1.21
1-Wochen-Bereich:
$1.16
$1.25
52-Wochen-Spanne:
$0.65
$15.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Firmenname
Citius Pharmaceuticals Inc
Sektor
Branche
Telefon
(908) 967-6676
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Vergleichen Sie CTXR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.21 | 20.58M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire
Citius Oncology raises $9 million in stock offering By Investing.com - Investing.com Australia
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement - Nasdaq
Citius Oncology Raises $9 Mln Through Direct Offering And Private Placement - Nasdaq
Will Citius Pharmaceuticals Inc. benefit from rate cutsEarnings Miss & Fast Gain Swing Alerts - Lancaster City Council
Citius Oncology raises $9 million in stock offering - Investing.com
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement - Benzinga
Can Citius Pharmaceuticals Inc. scale operations efficientlyInsider Selling & Short-Term High Return Ideas - Lancaster City Council
Citius Pharmaceuticals Inc. Moves Into Overbought Range Analysts Cautious2025 Valuation Update & Reliable Entry Point Alerts - beatles.ru
Is Citius Pharmaceuticals Inc. part of any major index2025 Macro Impact & Verified Entry Point Detection - classian.co.kr
Cannabis Stocks News - marketexclusive.com
Is Citius Pharmaceuticals Inc. a cyclical or defensive stock2025 Risk Factors & Safe Entry Zone Identification - beatles.ru
Does Citius Pharmaceuticals Inc. outperform in volatile markets2025 Key Highlights & Daily Profit Maximizing Tips - خودرو بانک
Citius Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Rallies & Intraday High Probability Alerts - Newser
Is Citius Pharmaceuticals Inc. a momentum stockQuarterly Performance Summary & Expert Approved Trade Ideas - خودرو بانک
Will Citius Pharmaceuticals Inc. stock go up in YEARWeekly Market Summary & Accurate Entry/Exit Alerts - خودرو بانک
Volume spikes in Citius Pharmaceuticals Inc. stock – what they meanBond Market & Long-Term Safe Investment Plans - Newser
Can volume confirm reversal in Citius Pharmaceuticals Inc.2025 Price Momentum & Risk Controlled Daily Trade Plans - Newser
Should you hold or exit Citius Pharmaceuticals Inc. now2025 Biggest Moves & AI Driven Stock Reports - Newser
Is Citius Pharmaceuticals Inc. stock showing strong momentumEarnings Miss & Precise Entry and Exit Recommendations - خودرو بانک
Is Citius Pharmaceuticals Inc. building a consolidation baseCEO Change & Daily Stock Trend Reports - Newser
Why Citius Pharmaceuticals Inc. is moving todayWeekly Stock Report & High Yield Stock Recommendations - Newser
Using economic indicators to assess Citius Pharmaceuticals Inc. potentialIPO Watch & Safe Capital Preservation Plans - Newser
What the charts say about Citius Pharmaceuticals Inc. todayJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
Will Citius Pharmaceuticals Inc. see short term momentumInsider Buying & Weekly Watchlist for Consistent Profits - Newser
Analyzing net buyer seller activity in Citius Pharmaceuticals Inc.July 2025 Opening Moves & Weekly Momentum Stock Picks - Newser
Citius Oncology Deploys AI Platform to Amplify the Performance of Its Commercial Team Ahead of LYMPHIR Launch - 富途牛牛
Will Citius Pharmaceuticals Inc. stock recover after recent dropGap Down & Comprehensive Market Scan Insights - Newser
Chart based analysis of Citius Pharmaceuticals Inc. trendsEarnings Recap Report & Low Drawdown Investment Ideas - Newser
What is Citius Pharmaceuticals Inc. s debt to equity ratioJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - خودرو بانک
Order flow analysis tools used on Citius Pharmaceuticals Inc.Global Markets & Expert Curated Trade Setup Alerts - Newser
Is Citius Pharmaceuticals Inc. showing insider buyingMarket Growth Report & Consistent Growth Stock Picks - خودرو بانک
Citius Pharmaceuticals Inc. stock trend forecastEarnings Beat & Weekly High Potential Stock Alerts - Newser
What data driven models say about Citius Pharmaceuticals Inc.’s futurePrice Action & Stepwise Entry and Exit Trade Signals - Newser
Will Citius Pharmaceuticals Inc. outperform the market2025 Price Momentum & Advanced Technical Signal Analysis - Newser
Citius Pharmaceuticals Soars 10.71% on Strategic Initiatives - AInvest
Citius Pharmaceuticals (CTXR) Soars 10.71% on Market Momentum - AInvest
Does Citius Pharmaceuticals Inc. qualify in momentum factor screeningJuly 2025 Setups & Safe Capital Allocation Plans - Newser
Citius Pharmaceuticals Inc. stock trendline breakdownGold Moves & Free Safe Entry Trade Signal Reports - Newser
Is Citius Pharmaceuticals Inc. trending in predictive chart modelsQuarterly Portfolio Report & Free Community Supported Trade Ideas - Newser
Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):